»

[Joe]

Originally Posted by piccooar PPHM is having a bit of a breakout today. Might jump in for a ride this afternoon.

I got in and out for a quick 15% profit today. Thanks for the heads up.

[Stuck-Market]

Can anyone familiar with BVTI share some insights on the company ? Looks like a trend is developing - not many shares but the share price is starting to move in the positive teritory. Phase III results on their cancer drug is expected .
Cheers
S

[SK_]

BVTI.PK Interesting... I don't have it on my FDA list. Do a little research Stuck-Market and pls post links, etc. ... I'll look as well.


Personalized Anti-Cancer Vaccine Pivotal Phase III Results to be Presented at ASCO Plenary Session


TAMPA, Fla.--(BUSINESS WIRE)--Biovest International, Inc. (Other OTC:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC:ABPIQ), today announced that BiovaxID®, Biovest’s personalized anti-cancer vaccine targeting B-cell blood cancers, will be featured in an oral presentation during the Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31^st, 2009 in Orlando, Florida.

Stephen J. Schuster, M.D., Associate Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, will deliver the BiovaxID presentation titled, “Idiotype Vaccine Therapy (BiovaxID®) in Follicular Lymphoma in First Complete Remission: Phase III Clinical Trial Results.”
Note to editors: Pursuant to ASCO policy, this abstract is embargoed until 10:30 a.m. (EDT) on Sunday, May 31^st, when it will be highlighted during ASCO’s official Press Program to the media.

Dr. Schuster’s oral presentation is scheduled to be the second of four clinical trial results presentations at the ASCO Plenary Session on Sunday, which begins at 1:00 p.m. (EDT) at the Orlando Convention Center location Level 2, West Hall D2.

In addition to the Plenary Session, BiovaxID will also be featured in a presentation to be delivered at ASCO by Larry Kwak, M.D., Ph.D., Chairman of the Department of Lymphoma and Myeloma and Associate Director of the Center for Cancer Immunology Research at the University of Texas M.D. Anderson Cancer Center. Dr. Kwak’s presentation will be part of a Panel Education Session titled, “Cancer Vaccines: Where do we go from here?” This presentation is scheduled for Sunday, May 31^st at 4:45 p.m. (EDT) at location Level 2, West Hall F1.

Any parties interested in meeting with the Biovest team at ASCO may contact Douglas Calder at 813-864-2558 or at dwcalder@biovest.com.

About BiovaxID®
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma.

A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells grow and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell’s surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient’s tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient’s T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. Unlike other failed cancer vaccine therapies that attempted to target lymphoma, BiovaxID is the only hybridoma (fusion of human lymphocyte with cancer cell) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as “training” the immune system to maintain continuous response if cancerous cells were to return.

About Biovest International, Inc.
Biovest International, Inc. (Other OTC: BVTI) is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned (75%) subsidiary of Accentia Biopharmaceuticals, Inc. (Other OTC: ABPIQ) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest recently completed a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.

[Kordoyn]

CRGN

Is doing well today. They have a boatload of cash, about 3 or 4 years worth, Japanese investors interested in their drugs, willingness to sell themselves (rawr) and will be presenting at ASCO looking for partners.

[GypsyDRB]

CRGN is one I'd like to buy into...but don't have the funds until one of my others (ahem...HEB...ahem) gaps up or takes off on approval news.

Also like ICAD from the biomedreports site (read some data about there virtual colonoscopy tech that said it has a 94% accuracy rate for determining cancerous tissue without doing a colonoscopy. I bought into it with a small position 1900 shares @ .2799

[pisssed]

CTHP

I don't know anything about this stock but almost every time news comes along it jumps BUT (strangely from.30-2.00?) Wac on googles most googled list.

NEWS:Cancer Therapeutics Finalizes Definitive Agreement With NanoTherapies, LLC

CTHP - Cancer Therapeutics Inc - Google Finance

Cancer reseach(home)

[mahmissa]

Hi all- I am looking to buy some stock going into the ASCO conference. Suggestions are greatly appreciated. I am picking up BVTI and thinking about CRGN and MELA.

[Kordoyn]

BUYOUT PLAY

CLDX is acquiring CRGN for a reported $95 million. This translates to roughly $1.65 per share.

Personally I think that is a steal for a company with $80 million cash holdings and a phase 2 cancer drug that works. I wouldn't be surprised if CLDX stock goes up more than CRGN stock.

RTTNews - Quick facts Articles, Positive EPS Surprises, News Analysis, Earnings, Audio News....

[Dead Bird Dog]

You may be right. CLDX is up to $9.29 from $8.13 in both AH and PM so far. We thought initially that the Pfizer buyout was responsible in this thread:

URGENT - PFIZER BUYOUT ... BUT WHO???

but it now seems that that target may actually be ICX.L. I wonder what kind of ride we may see today...

[mahmissa]

Congrats, Kordoyn. That should make for a nice pop and profit for you.